The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

Talazoparib plus enzalutamide met the primary endpoint in TALAPRO-2, lowering radiographic progression or death risk by 37% versus enzalutamide, with median rPFS not reached. Efficacy signals extended ...

A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer Institute and professor of internal medicine at the University of Utah (the U), has ...

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

A large analysis of two major clinical trials has found that the spread of prostate cancer can be detected on imaging scans even when biomarkers remain stable in patients treated with androgen ...

Truqap extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer compared to placebo, with a median rPFS of 33.2 months. Truqap was associated with higher rates of ...

Prostate cancer is one of the most frequently diagnosed cancers in men yet is often highly treatable when detected early. It originates in the prostate gland, located between the bladder and the penis ...

Prostate cancer is one of the most common cancers affecting men, yet it often goes unnoticed in its early stages because ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...